The role of lipoxygenases in pathophysiology; new insights and future perspectives

Redox Biology

Volumn 6, Issue , 2015, Pages 297-310

  Mashima, Ryuichi ^a   Okuyama, Torayuki ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Lipoxygenase; Phenotype; Resolvins; Signal transduction

Indexed keywords

12 LIPOXYGENASE 12 R TYPE; 15 LIPOXYGENASE TYPE B; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ALLERGEN; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; EPIDERMAL LIPOXYGENASE 3; FIBOFLAPON; FLUTICASONE PROPIONATE; HYDROPEROXYOCTADECAENOIC ACID; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; LEUKOTRIENE A4; LINOLEIC ACID; LIPID HYDROPEROXIDE; LIPOXYGENASE; MICRORNA; MONTELUKAST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE C; STAT6 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ZILEUTON; 3-(3-TERT-BUTYLSULFANYL-1-(4-(6-ETHOXYPYRIDIN-3-YL)BENZYL)-5-(5-METHYLPYRIDIN-2-YLMETHOXY)-1H-INDOL-2-YL)-2,2-DIMETHYLPROPIONIC ACID; ALOX12 PROTEIN, HUMAN; ALOX12B PROTEIN, HUMAN; ALOX15 PROTEIN, HUMAN; ALOX15B PROTEIN, HUMAN; ALOX5AP PROTEIN, HUMAN; ALOXE3 PROTEIN, HUMAN; ANTIASTHMATIC AGENT; INDOLE DERIVATIVE; VALERIC ACID DERIVATIVE;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALOX12 GENE; ALOX12B GENE; ALOX15 GENE; ALOX15B GENE; ALOX5 GENE; ALOXE3 GENE; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANXIETY DISORDER; APC GENE; APOPTOSIS; ASTHMA; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS; BONE DENSITY; BONE MARROW CELL; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE PREDISPOSITION; DNA METHYLATION; DRUG BLOOD LEVEL; EC50; ENCEPHALITIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; EPITHELIUM CELL; FORCED EXPIRATORY VOLUME; GENE; GENE EXPRESSION; GENE MUTATION; HEART PROTECTION; HEMATOPOIETIC STEM CELL; HISTONE MODIFICATION; HUMAN; ICHTHYOSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIPID PEROXIDATION; MACROPHAGE; MESENCHYMAL STEM CELL; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PAPILLOMA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TRANSPLANTATION; SMOOTH MUSCLE FIBER; TH2 CELL; THROMBOCYTOPENIA; TOXOPLASMA GONDII; TREATMENT RESPONSE; ANIMAL; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; NEOPLASMS; PATHOLOGY;

MAMMALIA; MUS;

5-LIPOXYGENASE-ACTIVATING PROTEINS; ANIMALS; ANTI-ASTHMATIC AGENTS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ASTHMA; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION; HUMANS; ICHTHYOSIS; INDOLES; LIPOXYGENASE; MICE; NEOPLASMS; PENTANOIC ACIDS;

EID: 84939797037     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.08.006     Document Type: Review

References (176)

1. Brash A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 1999, 274:23679-23682.
2. Radmark O., Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. J. Lipid Res. 2009, 50(Suppl):S40-S45.
3. Schneider C., Pratt D.A., Porter N.A., Brash A.R. Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Chem. Biol. 2007, 14:473-488.
4. Xu S., Mueser T.C., Marnett L.J., Funk M.O. Crystal structure of 12-lipoxygenase catalytic-domain-inhibitor complex identifies a substrate-binding channel for catalysis. Structure 2012, 20:1490-1497.
5. Gilbert N.C., Bartlett S.G., Waight M.T., Neau D.B., Boeglin W.E., Brash A.R., Newcomer M.E. The structure of human 5-lipoxygenase. Science 2011, 331:217-219.
6. Werz O. Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Planta medica 2007, 73:1331-1357.
7. Pettersen D., Davidsson O., Whatling C. Recent advances for FLAP inhibitors. Bioorg. Med. Chem. Lett. 2015, 25:2607-2612.
8. Krieg P., Marks F., Furstenberger G. A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: cloning, physical mapping, and expression. Genomics 2001, 73:323-330.
9. Nassar G.M., Morrow J.D., Roberts L.J., Lakkis F.G., Badr K.F. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 1994, 269:27631-27634.
10. Conrad D.J., Lu M. Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am. J. Respir. Cell Mol. Biol. 2000, 22:226-234.
11. Shureiqi I., Chen D., Lee J.J., Yang P., Newman R.A., Brenner D.E., Lotan R., Fischer S.M., Lippman S.M. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J. Natl. Cancer Inst. 2000, 92:1136-1142.
12. Kelavkar U.P., Harya N.S., Hutzley J., Bacich D.J., Monzon F.A., Chandran U., Dhir R., O'Keefe D.S. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins Other Lipid Mediat. 2007, 82:185-197.
13. Shankaranarayanan P., Chaitidis P., Kuhn H., Nigam S. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J. Biol. Chem. 2001, 276:42753-42760.
14. Liu C., Xu D., Han H., Fan Y., Schain F., Xu Z., Claesson H.E., Bjorkholm M., Sjoberg J. Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation. PLoS One 2012, 7:e52703.
15. Zuo X., Morris J.S., Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. J. Biol. Chem. 2008, 283:31341-31347.
16. Zuo X., Morris J.S., Broaddus R., Shureiqi I. 15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells. Oncogene 2009, 28:1496-1505.
17. Shureiqi I., Jiang W., Zuo X., Wu Y., Stimmel J.B., Leesnitzer L.M., Morris J.S., Fan H.Z., Fischer S.M., Lippman S.M. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:9968-9973.
18. Kelavkar U.P., Parwani A.V., Shappell S.B., Martin W.D. Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia 2006, 8:510-522.
19. Cyrus T., Witztum J.L., Rader D.J., Tangirala R., Fazio S., Linton M.F., Funk C.D. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Investig. 1999, 103:1597-1604.
20. Zhao L., Pratico D., Rader D.J., Funk C.D. 12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat. 2005, 78:185-193.
21. Huo Y., Zhao L., Hyman M.C., Shashkin P., Harry B.L., Burcin T., Forlow S.B., Stark M.A., Smith D.F., Clarke S., Srinivasan S., Hedrick C.C., Pratico D., Witztum J.L., Nadler J.L., Funk C.D., Ley K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004, 110:2024-2031.
22. Rong S., Cao Q., Liu M., Seo J., Jia L., Boudyguina E., Gebre A.K., Colvin P.L., Smith T.L., Murphy R.C., Mishra N., Parks J.S. Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis. J. Lipid Res. 2012, 53:686-695.
23. George J., Afek A., Shaish A., Levkovitz H., Bloom N., Cyrus T., Zhao L., Funk C.D., Sigal E., Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 2001, 104:1646-1650.
24. Reddy M.A., Kim Y.S., Lanting L., Natarajan R. Reduced growth factor responses in vascular smooth muscle cells derived from 12/15-lipoxygenase-deficient mice. Hypertension 2003, 41:1294-1300.
25. Gabel S.A., London R.E., Funk C.D., Steenbergen C., Murphy E. Leukocyte-type 12-lipoxygenase-deficient mice show impaired ischemic preconditioning-induced cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H1963-H1969.
26. Sun D., Funk C.D. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J. Biol. Chem. 1996, 271:24055-24062.
27. Kinder M., Thompson J.E., Wei C., Shelat S.G., Blair I.A., Carroll M., Pure E. Interferon regulatory factor-8-driven myeloid differentiation is regulated by 12/15-lipoxygenase-mediated redox signaling. Exp. Hematol. 2010, 38(1036-1046):e1031-e1034.
28. Kronke G., Uderhardt S., Katzenbeisser J., Schett G. The 12/15-lipoxygenase pathway promotes osteoclast development and differentiation. Autoimmunity 2009, 42:383-385.
29. Nunemaker C.S., Chen M., Pei H., Kimble S.D., Keller S.R., Carter J.D., Yang Z., Smith K.M., Wu R., Bevard M.H., Garmey J.C., Nadler J.L. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1065-E1075.
30. Brash A.R., Boeglin W.E., Chang M.S. Discovery of a second 15S-lipoxygenase in humans. Proc. Natl. Acad. Sci. USA 1997, 94:6148-6152.
31. Jisaka M., Kim R.B., Boeglin W.E., Brash A.R. Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. J. Biol. Chem. 2000, 275:1287-1293.
32. Gertow K., Nobili E., Folkersen L., Newman J.W., Pedersen T.L., Ekstrand J., Swedenborg J., Kuhn H., Wheelock C.E., Hansson G.K., Hedin U., Haeggstrom J.Z., Gabrielsen A. 12- and 15-lipoxygenases in human carotid atherosclerotic lesions: associations with cerebrovascular symptoms. Atherosclerosis 2011, 215:411-416.
33. Hulten L.M., Olson F.J., Aberg H., Carlsson J., Karlstrom L., Boren J., Fagerberg B., Wiklund O. 15-Lipoxygenase-2 is expressed in macrophages in human carotid plaques and regulated by hypoxia-inducible factor-1alpha. Eur. J. Clin. Investig. 2010, 40:11-17.
34. Magnusson L.U., Lundqvist A., Karlsson M.N., Skalen K., Levin M., Wiklund O., Boren J., Hulten L.M. Arachidonate 15-lipoxygenase type B knockdown leads to reduced lipid accumulation and inflammation in atherosclerosis. PLoS One 2012, 7:e43142.
35. Xu X.C., Shappell S.B., Liang Z., Song S., Menter D., Subbarayan V., Iyengar S., Tang D.G., Lippman S.M. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 2003, 5:121-127.
36. Soon P.S., Libe R., Benn D.E., Gill A., Shaw J., Sywak M.S., Groussin L., Bertagna X., Gicquel C., Bertherat J., McDonald K.L., Sidhu S.B., Robinson B.G. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann. Surg. 2008, 247:157-164.
37. Subbarayan V., Xu X.C., Kim J., Yang P., Hoque A., Sabichi A.L., Llansa N., Mendoza G., Logothetis C.J., Newman R.A., Lippman S.M., Menter D.G. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 2005, 7:280-293.
38. Feng Y., Bai X., Yang Q., Wu H., Wang D. Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells. Int. J. Oncol. 2010, 36:1541-1549.
39. Jiang W.G., Watkins G., Douglas-Jones A., Mansel R.E. Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot. Essent. Fatty Acids 2006, 74:235-245.
40. Wang D., Chen S., Feng Y., Yang Q., Campbell B.H., Tang X., Campbell W.B. Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumour Biol. 2006, 27:261-273.
41. Tang S., Bhatia B., Zhou J., Maldonado C.J., Chandra D., Kim E., Fischer S.M., Butler A.P., Friedman S.L., Tang D.G. Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene 2004, 23:6942-6953.
42. Daurkin I., Eruslanov E., Stoffs T., Perrin G.Q., Algood C., Gilbert S.M., Rosser C.J., Su L.M., Vieweg J., Kusmartsev S. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 2011, 71:6400-6409.
43. Vijil C., Hermansson C., Jeppsson A., Bergstrom G., Hulten L.M. Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. PLoS One 2014, 9:e88546.
44. Moran J.L., Qiu H., Turbe-Doan A., Yun Y., Boeglin W.E., Brash A.R., Beier D.R. A mouse mutation in the 12R-lipoxygenase, Alox12b, disrupts formation of the epidermal permeability barrier. J. Investig. Dermatol. 2007, 127:1893-1897.
45. Funk C.D. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta 1996, 1304:65-84.
46. Funk C.D., Chen X.S., Johnson E.N., Zhao L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat. 2002, 68-69:303-312.
47. Goodman J.E., Bowman E.D., Chanock S.J., Alberg A.J., Harris C.C. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004, 25:2467-2472.
48. Prasad V.V., Kolli P., Moganti D. Association of a functional polymorphism (Gln261Arg) in 12-lipoxygenase with breast cancer. Exp. Ther. Med. 2011, 2:317-323.
49. Fridman C., Ojopi E.P., Gregorio S.P., Ikenaga E.H., Moreno D.H., Demetrio F.N., Guimaraes P.E., Vallada H.P., Gattaz W.F., Dias Neto E. Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:40-43.
50. Kim T., Kim H.J., Park J.K., Kim J.W., Chung J.H. Association between polymorphisms of arachidonate 12-lipoxygenase (ALOX12) and schizophrenia in a Korean population. Behav. Brain Funct. 2010, 6:44.
51. Quintana L.F., Guzman B., Collado S., Claria J., Poch E. A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. Kidney Int. 2006, 69:526-530.
52. Gonzalez-Nunez D., Claria J., Rivera F., Poch E. Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 2001, 37:334-338.
53. Xiao W.J., He J.W., Zhang H., Hu W.W., Gu J.M., Yue H., Gao G., Yu J.B., Wang C., Ke Y.H., Fu W.Z., Zhang Z.L. ALOX12 polymorphisms are associated with fat mass but not peak bone mineral density in Chinese nuclear families. Int. J. Obes. 2011, 35:378-386.
54. Mullin B.H., Spector T.D., Curtis C.C., Ong G.N., Hart D.J., Hakim A.J., Worthy T., Wilson S.G. Polymorphisms in ALOX12, but not ALOX15, are significantly associated with BMD in postmenopausal women. Calcif. Tissue Int. 2007, 81:10-17.
55. Harslof T., Husted L.B., Nyegaard M., Carstens M., Stenkjaer L., Brixen K., Eiken P., Jensen J.E., Borglum A.D., Mosekilde L., Rejnmark L., Langdahl B.L. Polymorphisms in the ALOX12 gene and osteoporosis. Osteoporos. Int. 2011, 22:2249-2259.
56. Xiao W.J., Ke Y.H., He J.W., Zhang H., Yu J.B., Hu W.W., Gu J.M., Gao G., Yue H., Wang C., Hu Y.Q., Li M., Liu Y.J., Fu W.Z., Zhang Z.L. Polymorphisms in the human ALOX12 and ALOX15 genes are associated with peak bone mineral density in Chinese nuclear families. Osteoporos. Int. 2012, 23:1889-1897.
57. Ichikawa S., Koller D.L., Johnson M.L., Lai D., Xuei X., Edenberg H.J., Klein R.F., Orwoll E.S., Hui S.L., Foroud T.M., Peacock M., Econs M.J. Human ALOX12, but not ALOX15, is associated with BMD in white men and women. J. Bone Miner. Res. 2006, 21:556-564.
58. Kaur G., Jalagadugula G., Mao G., Rao A.K. RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood 2010, 115:3128-3135.
59. Kim S., Choi I.F., Quante J.R., Zhang L., Roop D.R., Koster M.I. p63 directly induces expression of Alox12, a regulator of epidermal barrier formation. Exp. Dermatol. 2009, 18:1016-1021.
60. Aleem A.M., Jankun J., Dignam J.D., Walther M., Kuhn H., Svergun D.I., Skrzypczak-Jankun E. Human platelet 12-lipoxygenase, new findings about its activity, membrane binding and low-resolution structure. J. Mol. Biol. 2008, 376:193-209.
61. Ohgami R.S., Ma L., Ren L., Weinberg O.K., Seetharam M., Gotlib J.R., Arber D.A. DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. Br. J. Haematol. 2012, 159:182-190.
62. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., Sekeres M., Saunthararajah Y., Maciejewski J.P. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113:1315-1325.
63. Kamitani H., Geller M., Eling T. The possible involvement of 15-lipoxygenase/leukocyte type 12-lipoxygenase in colorectal carcinogenesis. Adv. Exp. Med. Biol. 1999, 469:593-598.
64. Guo Y., Zhang X., Tan W., Miao X., Sun T., Zhao D., Lin D. Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet. Genom. 2007, 17:197-205.
65. Tan W., Wu J., Zhang X., Guo Y., Liu J., Sun T., Zhang B., Zhao D., Yang M., Yu D., Lin D. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007, 28:1197-1201.
66. Xu X.M., Yuan G.J., Deng J.J., Guo H.T., Xiang M., Yang F., Ge W., Chen S.Y. Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Hepatobiliary Pancreat. Dis. Int. 2012, 11:193-202.
67. Johnson E.N., Brass L.F., Funk C.D. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc. Natl. Acad. Sci. USA 1998, 95:3100-3105.
68. Virmani J., Johnson E.N., Klein-Szanto A.J., Funk C.D. Role of''platelet-type' 12-lipoxygenase in skin carcinogenesis. Cancer Lett. 2001, 162:161-165.
69. Johnson E.N., Nanney L.B., Virmani J., Lawson J.A., Funk C.D. Basal transepidermal water loss is increased in platelet-type 12-lipoxygenase deficient mice. J. Investig. Dermatol. 1999, 112:861-865.
70. Boeglin W.E., Kim R.B., Brash A.R. A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression. Proc. Natl. Acad. Sci. USA 1998, 95:6744-6749.
71. Sun D., McDonnell M., Chen X.S., Lakkis M.M., Li H., Isaacs S.N., Elsea S.H., Patel P.I., Funk C.D. Human 12(R)-lipoxygenase and the mouse ortholog. Molecular cloning, expression, and gene chromosomal assignment. J. Biol. Chem. 1998, 273:33540-33547.
72. Schneider C., Keeney D.S., Boeglin W.E., Brash A.R. Detection and cellular localization of 12R-lipoxygenase in human tonsils. Arch. Biochem. Biophys. 2001, 386:268-274.
73. Garcia-Verdugo I., BenMohamed F., Tattermusch S., Leduc D., Charpigny G., Chignard M., Ollero M., Touqui L. A role for 12R-lipoxygenase in MUC5AC expression by respiratory epithelial cells. Eur. Respir. J. 2012, 40:714-723.
74. Krieg P., Heidt M., Siebert M., Kinzig A., Marks F., Furstenberger G. Epidermis-type lipoxygenases. Adv. Exp. Med. Biol. 2002, 507:165-170.
75. Zheng Y., Yin H., Boeglin W.E., Elias P.M., Crumrine D., Beier D.R., Brash A.R. Lipoxygenases mediate the effect of essential fatty acid in skin barrier formation: a proposed role in releasing omega-hydroxyceramide for construction of the corneocyte lipid envelope. J. Biol. Chem. 2011, 286:24046-24056.
76. Herman M.L., Farasat S., Steinbach P.J., Wei M.H., Toure O., Fleckman P., Blake P., Bale S.J., Toro J.R. Transglutaminase-1 gene mutations in autosomal recessive congenital ichthyosis: summary of mutations (including 23 novel) and modeling of TGase-1. Hum. Mutat. 2009, 30:537-547.
77. Matsuki M., Yamashita F., Ishida-Yamamoto A., Yamada K., Kinoshita C., Fushiki S., Ueda E., Morishima Y., Tabata K., Yasuno H., Hashida M., Iizuka H., Ikawa M., Okabe M., Kondoh G., Kinoshita T., Takeda J., Yamanishi K. Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase). Proc. Natl. Acad. Sci. USA 1998, 95:1044-1049.
78. Brash A.R., Niraula N.P., Boeglin W.E., Mashhadi Z. An ancient relative of cyclooxygenase in cyanobacteria is a linoleate 10S-dioxygenase that works in tandem with a catalase-related protein with specific 10S-hydroperoxide lyase activity. J. Biol. Chem. 2014, 289:13101-13111.
79. Munoz-Garcia A., Thomas C.P., Keeney D.S., Zheng Y., Brash A.R. The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier. Biochim. Biophys. Acta 2014, 1841:401-408.
80. Krieg P., Furstenberger G. The role of lipoxygenases in epidermis. Biochim. Biophys. Acta 2014, 1841:390-400.
81. Lesueur F., Bouadjar B., Lefevre C., Jobard F., Audebert S., Lakhdar H., Martin L., Tadini G., Karaduman A., Emre S., Saker S., Lathrop M., Fischer J. Novel mutations in ALOX12B in patients with autosomal recessive congenital ichthyosis and evidence for genetic heterogeneity on chromosome 17p13. J. Investig. Dermatol. 2007, 127:829-834.
82. Eckl K.M., de Juanes S., Kurtenbach J., Natebus M., Lugassy J., Oji V., Traupe H., Preil M.L., Martinez F., Smolle J., Harel A., Krieg P., Sprecher E., Hennies H.C. Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B. J. Investig. Dermatol. 2009, 129:1421-1428.
83. Li H., Lorie E.P., Fischer J., Vahlquist A., Torma H. The expression of epidermal lipoxygenases and transglutaminase-1 is perturbed by NIPAL4 mutations: indications of a common metabolic pathway essential for skin barrier homeostasis. J. Investig. Dermatol. 2012, 132:2368-2375.
84. Jobard F., Lefevre C., Karaduman A., Blanchet-Bardon C., Emre S., Weissenbach J., Ozguc M., Lathrop M., Prud'homme J.F., Fischer J. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum. Mol. Genet. 2002, 11:107-113.
85. Harting M., Brunetti-Pierri N., Chan C.S., Kirby J., Dishop M.K., Richard G., Scaglia F., Yan A.C., Levy M.L. Self-healing collodion membrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene. Arch. Dermatol. 2008, 144:351-356.
86. Yu Z., Schneider C., Boeglin W.E., Brash A.R. Mutations associated with a congenital form of ichthyosis (NCIE) inactivate the epidermal lipoxygenases 12R LOX and eLOX3. Biochim. Biophys. Acta 2005, 1686:238-247.
87. Epp N., Furstenberger G., Muller K., de Juanes S., Leitges M., Hausser I., Thieme F., Liebisch G., Schmitz G., Krieg P. 12R-lipoxygenase deficiency disrupts epidermal barrier function. J. Cell Biol. 2007, 177:173-182.
88. de Juanes S., Epp N., Latzko S., Neumann M., Furstenberger G., Hausser I., Stark H.J., Krieg P. Development of an ichthyosiform phenotype in Alox12b-deficient mouse skin transplants. J. Invest. Dermatol. 2009, 129:1429-1436.
89. Segre J.A., Bauer C., Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat. Genet. 1999, 22:356-360.
90. Furuse M., Hata M., Furuse K., Yoshida Y., Haratake A., Sugitani Y., Noda T., Kubo A., Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 2002, 156:1099-1111.
91. Zheng Y., Brash A.R. On the role of molecular oxygen in lipoxygenase activation: comparison and contrast of epidermal lipoxygenase-3 with soybean lipoxygenase-1. J. Biol. Chem. 2010, 285:39876-39887.
92. Zheng Y., Brash A.R. Dioxygenase activity of epidermal lipoxygenase-3 unveiled: typical and atypical features of its catalytic activity with natural and synthetic polyunsaturated fatty acids. J. Biol. Chem. 2010, 285:39866-39875.
93. Yu Z., Schneider C., Boeglin W.E., Marnett L.J., Brash A.R. The lipoxygenase gene ALOXE3 implicated in skin differentiation encodes a hydroperoxide isomerase. Proc. Natl. Acad. Sci. USA 2003, 100:9162-9167.
94. Vahlquist A., Bygum A., Ganemo A., Virtanen M., Hellstrom-Pigg M., Strauss G., Brandrup F., Fischer J. Genotypic and clinical spectrum of self-improving collodion ichthyosis: ALOX12B, ALOXE3, and TGM1 mutations in Scandinavian patients. J. Invest. Dermatol. 2010, 130:438-443.
95. Krieg P., Rosenberger S., de Juanes S., Latzko S., Hou J., Dick A., Kloz U., van der Hoeven F., Hausser I., Esposito I., Rauh M., Schneider H. Aloxe3 knockout mice reveal a function of epidermal lipoxygenase-3 as hepoxilin synthase and its pivotal role in barrier formation. J. Invest. Dermatol. 2013, 133:172-180.
96. Duroudier N.P., Tulah A.S., Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009, 64:823-839.
97. Bai C., Matsui E., Ohnishi H., Kimata K., Kasahara K., Kaneko H., Kato Z., Fukao T., Kondo N. A novel polymorphism, E254K, in the 5-lipoxygenase gene associated with bronchial asthma. Int. J. Mol. Med. 2008, 21:139-144.
98. Kawagishi Y., Mita H., Taniguchi M., Maruyama M., Oosaki R., Higashi N., Kashii T., Kobayashi M., Akiyama K. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J. Allergy Clin. Immunol. 2002, 109:936-942.
99. Kim S.H., Bae J.S., Suh C.H., Nahm D.H., Holloway J.W., Park H.S. Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy 2005, 60:760-765.
100. Kleinstein S.E., Heath L., Makar K.W., Poole E.M., Seufert B.L., Slattery M.L., Xiao L., Duggan D.J., Hsu L., Curtin K., Koepl L., Muehling J., Taverna D., Caan B.J., Carlson C.S., Potter J.D., Ulrich C.M. Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia. Genes Chromosom. Cancer 2013, 52:437-449.
101. White K.L., Schildkraut J.M., Palmieri R.T., Iversen E.S., Berchuck A., Vierkant R.A., Rider D.N., Charbonneau B., Cicek M.S., Sutphen R., Birrer M.J., Pharoah P.P., Song H., Tyrer J., Gayther S.A., Ramus S.J., Wentzensen N., Yang H.P., Garcia-Closas M., Phelan C.M., Cunningham J.M., Fridley B.L., Sellers T.A., Goode E.L. Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res. 2012, 72:1064-1069.
102. Chen X.S., Sheller J.R., Johnson E.N., Funk C.D. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994, 372:179-182.
103. Goulet J.L., Snouwaert J.N., Latour A.M., Coffman T.M., Koller B.H. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. USA 1994, 91:12852-12856.
104. Cuzzocrea S., Rossi A., Serraino I., Di Paola R., Dugo L., Genovese T., Britti D., Sciarra G., De Sarro A., Caputi A.P., Sautebin L. 5-lipoxygenase knockout mice exhibit a resistance to acute pancreatitis induced by cerulein. Immunology 2003, 110:120-130.
105. Segal B.H., Kuhns D.B., Ding L., Gallin J.I., Holland S.M. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J. Leukoc. Biol. 2002, 71:410-416.
106. Blaho V.A., Zhang Y., Hughes-Hanks J.M., Brown C.R. 5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis. J. Immunol. 2011, 186:3076-3084.
107. Aliberti J., Serhan C., Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 2002, 196:1253-1262.
108. Irvin C.G., Tu Y.P., Sheller J.R., Funk C.D. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am. J. Physiol. 1997, 272:L1053-L1058.
109. Goulet J.L., Griffiths R.C., Ruiz P., Spurney R.F., Pisetsky D.S., Koller B.H., Coffman T.M. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J. Immunol. 1999, 163:359-366.
110. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J.N., Petasis N.A., Blumberg R.S., Serhan C.N. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 2005, 102:7671-7676.
111. Tjonahen E., Oh S.F., Siegelman J., Elangovan S., Percarpio K.B., Hong S., Arita M., Serhan C.N. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 2006, 13:1193-1202.
112. Arita M., Bianchini F., Aliberti J., Sher A., Chiang N., Hong S., Yang R., Petasis N.A., Serhan C.N. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005, 201:713-722.
113. Recchiuti A., Krishnamoorthy S., Fredman G., Chiang N., Serhan C.N. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 2011, 25:544-560.
114. Mehrabian M., Allayee H., Wong J., Shi W., Wang X.P., Shaposhnik Z., Funk C.D., Lusis A.J. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 2002, 91:120-126.
115. Yu Z., Crichton I., Tang S.Y., Hui Y., Ricciotti E., Levin M.D., Lawson J.A., Pure E., FitzGerald G.A. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc. Natl. Acad. Sci. USA 2012, 109:6727-6732.
116. Joshi Y.B., Pratico D. The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. Front. Cell. Neurosci. 2014, 8:436.
117. Joshi Y.B., Pratico D. Knockout of 5-lipoxygenase results in age-dependent anxiety-like behavior in female mice. PLoS One 2011, 6:e29448.
118. Chu J., Li J.G., Pratico D. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One 2013, 8:e70991.
119. Giannopoulos P.F., Chu J., Joshi Y.B., Sperow M., Li J.G., Kirby L.G., Pratico D. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol. Psychiatry 2014, 19:511-518.
120. Gounari F., Chang R., Cowan J., Guo Z., Dose M., Gounaris E., Khazaie K. Loss of adenomatous polyposis coli gene function disrupts thymic development. Nat. Immunol. 2005, 6:800-809.
121. Cheon E.C., Strouch M.J., Krantz S.B., Heiferman M.J., Bentrem D.J. Genetic deletion of 5-lipoxygenase increases tumor-infiltrating macrophages in Apc(Delta468) mice. J. Gastrointest. Surg. 2012, 16:389-393.
122. Cheon E.C., Khazaie K., Khan M.W., Strouch M.J., Krantz S.B., Phillips J., Blatner N.R., Hix L.M., Zhang M., Dennis K.L., Salabat M.R., Heiferman M., Grippo P.J., Munshi H.G., Gounaris E., Bentrem D.J. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res. 2011, 71:1627-1636.
123. Wimberly A.L., Forsyth C.B., Khan M.W., Pemberton A., Khazaie K., Keshavarzian A. Ethanol-induced mast cell-mediated inflammation leads to increased susceptibility of intestinal tumorigenesis in the APC Delta468 min mouse model of colon cancer. Alcohol Clin. Exp. Res. 2013, 37(Suppl 1):E199-E208.
124. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. 2005, 4:664-672.
125. Sampson A.P. FLAP inhibitors for the treatment of inflammatory diseases. Curr. Opin. Investig. Drugs 2009, 10:1163-1172.
126. Holloway J.W., Barton S.J., Holgate S.T., Rose-Zerilli M.J., Sayers I. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy 2008, 63:1046-1053.
127. Byrum R.S., Goulet J.L., Griffiths R.J., Koller B.H. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J. Exp. Med. 1997, 185:1065-1075.
128. Strom J.O., Strid T., Hammarstrom S. Disruption of the alox5ap gene ameliorates focal ischemic stroke: possible consequence of impaired leukotriene biosynthesis. BMC Neurosci. 2012, 13:146.
129. Griffiths R.J., Smith M.A., Roach M.L., Stock J.L., Stam E.J., Milici A.J., Scampoli D.N., Eskra J.D., Byrum R.S., Koller B.H., McNeish J.D. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J. Exp. Med. 1997, 185:1123-1129.
130. Jawien J., Gajda M., Rudling M., Mateuszuk L., Olszanecki R., Guzik T.J., Cichocki T., Chlopicki S., Korbut R. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Investig. 2006, 36:141-146.
131. Jawien J., Gajda M., Olszanecki R., Korbut R. BAY x 1005 attenuates atherosclerosis in apoE/LDLR-double knockout mice. J. Physiol. Pharmacol. 2007, 58:583-588.
132. Back M., Sultan A., Ovchinnikova O., Hansson G.K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 2007, 100:946-949.
133. Giannopoulos P.F., Chu J., Joshi Y.B., Sperow M., Li J.G., Kirby L.G., Pratico D. 5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. Biol. Psychiatry 2013, 74:348-356.
134. Joshi Y.B., Chu J., Pratico D. Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. Aging Cell 2013, 12:706-711.
135. Steinhilber D., Hofmann B. Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin. Pharmacol. Toxicol. 2014, 114:70-77.
136. van Leyen K. Lipoxygenase: an emerging target for stroke therapy. CNS Neurol. Disord. Drug Targets 2013, 12:191-199.
137. Bain G., King C.D., Brittain J., Hartung J.P., Dearmond I., Stearns B., Truong Y.P., Hutchinson J.H., Evans J.F., Holme K. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2. J. Clin. Pharmacol. 2012, 52:1482-1493.
138. Follows R.M., Snowise N.G., Ho S.Y., Ambery C.L., Smart K., McQuade B.A. Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir. Res. 2013, 14:54.
139. Singh D., Boyce M., Norris V., Kent S.E., Bentley J.H. Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study. Int. J. Gen. Med. 2013, 6:897-903.
140. Assimes T.L., Knowles J.W., Priest J.R., Basu A., Borchert A., Volcik K.A., Grove M.L., Tabor H.K., Southwick A., Tabibiazar R., Sidney S., Boerwinkle E., Go A.S., Iribarren C., Hlatky M.A., Fortmann S.P., Myers R.M., Kuhn H., Risch N., Quertermous T. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis 2008, 198:136-144.
141. Habermann N., Ulrich C.M., Lundgreen A., Makar K.W., Poole E.M., Caan B., Kulmacz R., Whitton J., Galbraith R., Potter J.D., Slattery M.L. PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer. Genes Nutr. 2013, 8:115-126.
142. Kraus S., Hummler S., Toriola A.T., Poole E.M., Scherer D., Kotzmann J., Makar K.W., Kazanov D., Galazan L., Naumov I., Coghill A.E., Duggan D., Gigic B., Arber N., Ulrich C.M. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenet. Genom. 2013, 23:428-437.
143. Urano T., Shiraki M., Fujita M., Hosoi T., Orimo H., Ouchi Y., Inoue S. Association of a single nucleotide polymorphism in the lipoxygenase ALOX15 5'-flanking region (-5229G/A) with bone mineral density. J. Bone Miner. Metab. 2005, 23:226-230.
144. Cheung C.L., Chan V., Kung A.W. A differential association of ALOX15 polymorphisms with bone mineral density in pre- and post-menopausal women. Hum. Hered. 2008, 65:1-8.
145. Wuest S.J., Horn T., Marti-Jaun J., Kuhn H., Hersberger M. Association of polymorphisms in the ALOX15B gene with coronary artery disease. Clin. Biochem. 2014, 47:349-355.
146. Burdon K.P., Rudock M.E., Lehtinen A.B., Langefeld C.D., Bowden D.W., Register T.C., Liu Y., Freedman B.I., Carr J.J., Hedrick C.C., Rich S.S. Human lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart study. Mediat. Inflamm. 2010, 2010:170153.
147. Witola W.H., Liu S.R., Montpetit A., Welti R., Hypolite M., Roth M., Zhou Y., Mui E., Cesbron-Delauw M.F., Fournie G.J., Cavailles P., Bisanz C., Boyer K., Withers S., Noble A.G., Swisher C.N., Heydemann P.T., Rabiah P., Muench S.P., McLeod R. ALOX12 in human toxoplasmosis. Infect. Immun. 2014, 82:2670-2679.
148. Resler A.J., Makar K.W., Heath L., Whitton J., Potter J.D., Poole E.M., Habermann N., Scherer D., Duggan D., Wang H., Lindor N.M., Passarelli M.N., Baron J.A., Newcomb P.A., Le Marchand L., Ulrich C.M. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis 2014, 35:2121-2126.
149. Gong Z., Hebert J.R., Bostick R.M., Deng Z., Hurley T.G., Dixon D.A., Nitcheva D., Xie D. Common polymorphisms in 5-lipoxygenase and 12-lipoxygenase genes and the risk of incident, sporadic colorectal adenoma. Cancer 2007, 109:849-857.
150. Xiong D.H., Shen H., Zhao L.J., Xiao P., Yang T.L., Guo Y., Wang W., Guo Y.F., Liu Y.J., Recker R.R., Deng H.W. Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction. J. Bone Miner. Res. 2006, 21:1678-1695.
151. Israeli S., Goldberg I., Fuchs-Telem D., Bergman R., Indelman M., Bitterman-Deutsch O., Harel A., Mashiach Y., Sarig O., Sprecher E. Non-syndromic autosomal recessive congenital ichthyosis in the Israeli population. Clin. Exp. Dermatol. 2013, 38:911-916.
152. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., Lusis A.J., Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 2004, 350:29-37.
153. Spanbroek R., Grabner R., Lotzer K., Hildner M., Urbach A., Ruhling K., Moos M.P., Kaiser B., Cohnert T.U., Wahlers T., Zieske A., Plenz G., Robenek H., Salbach P., Kuhn H., Radmark O., Samuelsson B., Habenicht A.J. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 2003, 100:1238-1243.
154. Kalayci O., Birben E., Sackesen C., Keskin O., Tahan F., Wechsler M.E., Civelek E., Soyer O.U., Adalioglu G., Tuncer A., Israel E., Lilly C. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 2006, 61:97-103.
155. Choi J.H., Park H.S., Oh H.B., Lee J.H., Suh Y.J., Park C.S., Shin H.D. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum. Genet. 2004, 114:337-344.
156. Via M., De Giacomo A., Corvol H., Eng C., Seibold M.A., Gillett C., Galanter J., Sen S., Tcheurekdjian H., Chapela R., Rodriguez-Santana J.R., Rodriguez-Cintron W., Thyne S., Avila P.C., Choudhry S., Gonzalez Burchard E. The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. Clin. Exp. Allergy 2010, 40:582-589.
157. Kronke G., Katzenbeisser J., Uderhardt S., Zaiss M.M., Scholtysek C., Schabbauer G., Zarbock A., Koenders M.I., Axmann R., Zwerina J., Baenckler H.W., van den Berg W., Voll R.E., Kuhn H., Joosten L.A., Schett G. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J. Immunol. 2009, 183:3383-3389.
158. Secor W.E., Powell M.R., Morgan J., Wynn T.A., Funk C.D. Mice deficient for 5-lipoxygenase, but not leukocyte-type 12-lipoxygenase, display altered immune responses during infection with Schistosoma mansoni. Prostaglandins Other Lipid Mediat. 1998, 56:291-304.
159. Jeon S.G., Moon H.G., Kim Y.S., Choi J.P., Shin T.S., Hong S.W., Tae Y.M., Kim S.H., Zhu Z., Gho Y.S., Kim Y.K. 15-lipoxygenase metabolites play an important role in the development of a T-helper type 1 allergic inflammation induced by double-stranded RNA. Clin. Exp. Allergy 2009, 39:908-917.
160. Zhao L., Cuff C.A., Moss E., Wille U., Cyrus T., Klein E.A., Pratico D., Rader D.J., Hunter C.A., Pure E., Funk C.D. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J. Biol. Chem. 2002, 277:35350-35356.
161. Zarbock A., Distasi M.R., Smith E., Sanders J.M., Kronke G., Harry B.L., von Vietinghoff S., Buscher K., Nadler J.L., Ley K. Improved survival and reduced vascular permeability by eliminating or blocking 12/15-lipoxygenase in mouse models of acute lung injury (ALI). J. Immunol. 2009, 183:4715-4722.
162. Uderhardt S., Herrmann M., Oskolkova O.V., Aschermann S., Bicker W., Ipseiz N., Sarter K., Frey B., Rothe T., Voll R., Nimmerjahn F., Bochkov V.N., Schett G., Kronke G. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 2012, 36:834-846.
163. Obrosova I.G., Stavniichuk R., Drel V.R., Shevalye H., Vareniuk I., Nadler J.L., Schmidt R.E. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am. J. Pathol. 2010, 177:1436-1447.
164. Sears D.D., Miles P.D., Chapman J., Ofrecio J.M., Almazan F., Thapar D., Miller Y.I. 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009, 4:e7250.
165. Kundumani-Sridharan V., Niu J., Wang D., Van Quyen D., Zhang Q., Singh N.K., Subramani J., Karri S., Rao G.N. 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Src-mediated Egr-1-dependent rapid induction of FGF-2 expression. Blood 2010, 115:2105-2116.
166. Singh N.K., Kundumani-Sridharan V., Rao G.N. 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation. Blood 2011, 118:5701-5712.
167. Cole B.K., Kuhn N.S., Green-Mitchell S.M., Leone K.A., Raab R.M., Nadler J.L., Chakrabarti S.K. 12/15-Lipoxygenase signaling in the endoplasmic reticulum stress response. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E654-E665.
168. Kriska T., Cepura C., Magier D., Siangjong L., Gauthier K.M., Campbell W.B. Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H2428-H2438.
169. Leedom A.J., Sullivan A.B., Dong B., Lau D., Gronert K. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am. J. Pathol. 2010, 176:74-84.
170. Martinez-Clemente M., Ferre N., Titos E., Horrillo R., Gonzalez-Periz A., Moran-Salvador E., Lopez-Vicario C., Miquel R., Arroyo V., Funk C.D., Claria J. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology 2010, 52:1980-1991.
171. Stavniichuk R., Shevalye H., Hirooka H., Nadler J.L., Obrosova I.G. Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy. Biochem. Pharmacol. 2012, 83:932-940.
172. Mabalirajan U., Rehman R., Ahmad T., Kumar S., Leishangthem G.D., Singh S., Dinda A.K., Biswal S., Agrawal A., Ghosh B. 12/15-lipoxygenase expressed in non-epithelial cells causes airway epithelial injury in asthma. Sci. Rep. 2013, 3:1540.
173. Fabre J.E., Goulet J.L., Riche E., Nguyen M., Coggins K., Offenbacher S., Koller B.H. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J. Clin. Investig. 2002, 109:1373-1380.
174. Secatto A., Rodrigues L.C., Serezani C.H., Ramos S.G., Dias-Baruffi M., Faccioli L.H., Medeiros A.I. 5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection. PLoS One 2012, 7:e31701.
175. Uz T., Dimitrijevic N., Tueting P., Manev H. 5-lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior. Restor. Neurol. Neurosci. 2002, 20:15-20.
176. Ichinose F., Zapol W.M., Sapirstein A., Ullrich R., Tager A.M., Coggins K., Jones R., Bloch K.D. Attenuation of hypoxic pulmonary vasoconstriction by endotoxemia requires 5-lipoxygenase in mice. Circ. Res. 2001, 88:832-838.